Keyphrases
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
100%
Cytoreductive Surgery
83%
Postoperative Morbidity
66%
Odds Ratio
50%
Confidence Interval
50%
Operative Time
50%
Postoperative Mortality
33%
Length of Stay
33%
Clinical Outcomes
33%
Logistic Regression Analysis
16%
Risk Factors
16%
Inclusion Criteria
16%
Postoperative Complications
16%
Patient Selection
16%
Identify Risk
16%
Colon
16%
Hematocrit
16%
Favorable Outcome
16%
Primary Tumor Site
16%
Temporal Trends
16%
Peritoneum
16%
Peritoneal Carcinomatosis
16%
American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP)
16%
Preoperative Serum Albumin
16%
Nursing and Health Professions
Cytoreductive Surgery
100%
Hyperthermic Intraperitoneal Chemotherapy
100%
Odds Ratio
50%
Confidence Interval
50%
Operation Duration
50%
Clinical Outcome
33%
Length of Stay
33%
Logistic Regression Analysis
16%
Total Quality Management
16%
Hematocrit
16%
Primary Tumor
16%
Postoperative Complication
16%
Serum Albumin
16%
Patient Selection
16%
Carcinomatous Peritonitis
16%
Medicine and Dentistry
Cytoreductive Surgery
100%
Hyperthermic Intraperitoneal Chemotherapy
100%
Odds Ratio
50%
Operation Duration
50%
Logistic Regression Analysis
16%
Surgeon
16%
Vermiform Appendix
16%
Primary Tumor
16%
Postoperative Complication
16%
Patient Selection
16%
Quality Improvement
16%
Colon
16%
Hematocrit
16%
Peritoneum
16%
Serum Albumin
16%
Carcinomatous Peritonitis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Intraperitoneal Chemotherapy
100%
Primary Tumor
16%
Postoperative Complication
16%
Serum Albumin
16%
Carcinomatous Peritonitis
16%